NervGen Pharma (NASDAQ:NGEN – Get Free Report) was upgraded by stock analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.
Several other equities analysts have also weighed in on the company. Leerink Partners assumed coverage on NervGen Pharma in a research note on Monday, July 13th. They issued an “outperform” rating and a $10.00 price objective on the stock. Weiss Ratings downgraded shares of NervGen Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 4th. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $14.00.
Check Out Our Latest Stock Analysis on NGEN
NervGen Pharma Price Performance
Shares of NervGen Pharma stock opened at $1.43 on Friday. NervGen Pharma has a twelve month low of $1.38 and a twelve month high of $6.30. The firm has a market capitalization of $115.30 million and a PE ratio of -3.11. The firm has a fifty day moving average price of $1.93.
NervGen Pharma (NASDAQ:NGEN – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.28). As a group, analysts predict that NervGen Pharma will post -0.55 EPS for the current fiscal year.
Hedge Funds Weigh In On NervGen Pharma
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Empery Asset Management LP purchased a new stake in NervGen Pharma during the 2nd quarter worth $8,240,000. Stonepine Capital Management LLC purchased a new position in NervGen Pharma in the second quarter valued at about $559,657. Finally, AXQ Capital LP purchased a new position in NervGen Pharma in the second quarter valued at about $89,000.
NervGen Pharma Company Profile
NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies designed to promote nervous system repair and functional recovery after injury or disease. The company is headquartered in Vancouver, British Columbia, and is listed on the Nasdaq Capital Market and the TSX Venture Exchange under the symbol NGEN.
NervGen’s lead product candidate is NVG-291, an investigational peptide intended to enhance the body’s natural capacity for neural repair by modulating the protein tyrosine phosphatase sigma receptor.
See Also
- Five stocks we like better than NervGen Pharma
- Newmont’s Record Quarter Shows Why Gold’s Floor Is the Real Story
- Albemarle Upgrade: Can Energy Storage Recharge Lithium’s Leader?
- Consumer Staples Are Up 12% This Year—These 3 Beverage Stocks Are Leading the Way
- Can Planet Fitness Get Its Growth Back in Shape?
Receive News & Ratings for NervGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NervGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
